CD3−CD16−CD56bright Immunoregulatory NK Cells are Increased in the Tumor Microenvironment and Inversely Correlate with Advanced Stages in Patients with Papillary Thyroid Cancer-Reference-Cited by-同舟云学术

CD3−CD16−CD56bright Immunoregulatory NK Cells are Increased in the Tumor Microenvironment and Inversely Correlate with Advanced Stages in Patients with Papillary Thyroid Cancer

Published:2013-12 Issue:12 Volume:23 Page:1561-1568
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Gogali Foteini¹,Paterakis George²,Rassidakis George Z.³,Liakou Chrysoula I.¹,Liapi Charis¹

Affiliation:

1. Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Greece.

2. Flow Cytometry Laboratory, Department of Immunology, Athens Regional General Hospital G. Gennimatas, Athens, Greece.

3. First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Greece.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2012.0560

Reference56 articles.

1. Biology of Natural Killer Cells

2. The biology of human natural killer-cell subsets

3. Innate or Adaptive Immunity? The Example of Natural Killer Cells

4. Human natural killer cells

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications;Frontiers in Immunology;2024-09-03

2. Biomarkers related to m6A and succinic acid metabolism in papillary thyroid carcinoma;BMC Medical Genomics;2024-08-07

3. Characterization of Immune Infiltrate Along the Leading Edge of Differentiated Thyroid Cancer;Thyroid®;2024-08-01

4. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy;Frontiers in Immunology;2024-05-29

5. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study;Nature Communications;2024-03-27